Fifteen patients with muscle invasive bladder cancer were treated between April 2021 and December 2022 on a ring-based linac integrated with a CBCT and software platform for both treatment planning and delivery (Ethos Therapy™, version 1.1, Varian a Siemens Healthineers Company, USA). The patients’ mean age was 68 years and the number of males and females was 11 and 4, respectively (see Additional file 1 ). In 20 fractions the bladder, urethra and first pelvic lymph nodes (elective volume) of each patient received a total dose of 40 Gy combined with a SIB of an additional 15 Gy to the tumor bed resulting in a total of 300 delivered fractions. Radiotherapy was combined with chemotherapy (Mitomycin-c/ Capecitabine).
Ethos therapy
Manufactured by Agilent Technologies
Sourced in United States
The Ethos Therapy is a laboratory equipment product offered by Agilent Technologies. It is designed to perform microwave-assisted sample preparation for various analytical applications. The core function of the Ethos Therapy is to facilitate efficient sample digestion and extraction processes.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using ethos therapy
1
Bladder Cancer Radiotherapy with Chemotherapy
2
CBCT-guided Radiotherapy for Prostate Cancer
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Between February and July 2020, eleven consecutive biopsy-proven intact prostate cancer patients underwent CBCT-guided oART with Ethos therapy (Varian Medical Systems, Palo Alto, CA). These patients were eligible within the time slot we had available. Patients with nodal involvement were excluded. All patients were treated using a fractionation scheme of 20 times 3 Gy to the prostate. For patients with more advanced stages, an additional total dose of 54 Gy (four patients) or 60 Gy (three patients) was given to the (base of the) seminal vesicles using a simultaneous integrated boost technique. The institutional review board of Medisch Spectrum Twente approved the study and judged that the study does not fall under the scope of the Medical Research Involving Human Subjects Act (WMO).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!